NeuroVive Pharmaceutical Asia has entered a collaboration agreement with Sanofi’s local subsidiary to develop and commercialise CicloMulsion in South Korea.

NeuroVive’s CicloMulsion, which is in a clinical development phase, is being developed to treat reperfusion injury in cardiovascular disease. It is claimed to be the first cyclophilin inhibitor being developed to treat reperfusion injury.

NeuroVive CEO Mikael Brönnegård said: “The collaboration with Sanofi will enable us to broaden the commercialisation of CicloMulsion for the treatment of cardiovascular disease.”

“The collaboration with Sanofi will enable us to broaden the commercialisation of CicloMulsion for the treatment of cardiovascular disease.”

Under the deal, NeuroVive Asia will receive an upfront payment from Sanofi, in addition to the conditional milestone payment and royalty on potential future sales in South Korea.

Under the agreement, Sanofi’s local affiliate will take responsibility for regulatory processes and market approval, launch, marketing, distribution and sales of CicloMulsion in South Korea.

NeuroVive will supply CicloMulsion to Sanofi for distribution and sale in South Korea, after its potential market launch.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Currently, CicloMulsion is being assessed to treat reperfusion injury following myocardial infarct in a European clinical phase III trial known as Circus study.

In addition, it is being evaluated to treat other acute heart and kidney injuries within the framework of the deal with Hospices Civils de Lyon and in a clinical phase II trial in collaboration with Skåne University Hospital in Lund of Sweden.

The results from the planned Asian Phase III trial, along with additional data from NeuroVive including the results of the current European Phase III study, will be used to gain market approval for CicloMulsion in different Asian countries to treat reperfusion injury following myocardial infarct.

Along with its collaboration partner China’s Sihuan Pharmaceuticals, NeuroVive Asia will carry out the planned Asian Phase III trial of CicloMulsion.